Nektar Therapeutics · NASDAQ:NKTR

Nektar Therapeutics — ACAAI Annual Scientific Meeting 2025

15 slides from Nektar Therapeutics's conference presentation, Nov 8, 2025

  1. Slide 1: Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial

    Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial Jonathan Corren1, Peter Lio2, Jonathan I. Silverberg3, Raj Chovatiya4,5, Melinda Gooderham6, Thomas Bieber7, Richard B. Warren8, Neil Sadick9,10, James R. Treat11, Spyridon Gkalpak

  2. Slide 2: Presenter and Conflicts

    Presenter and Conflicts James R. Treat, MD Professor of Clinical Pediatrics & Dermatology Department of General Pediatrics, Section of Dermatology The Children's Hospital of Philadelphia Philadelphia, PA, United States Conflict of Interest Disclosures: • Consultant: Arcutis Biotherapeutics, Nektar T

  3. Slide 3: Regulatory T Cells and Peripheral Immune Tolerance: Immune System's Security Guards

    Regulatory T Cells and Peripheral Immune Tolerance: “Immune System’s Security Guards” Discovery Served as Basis for 2025 Nobel Prize in Physiology and Medicine and MOA Represents a Novel Therapeutic Target Novel Therapeutic Strategies in Immunology  In a landmark 1995 study, Dr. Sakaguchi and colle

  4. Slide 4: REZOLVE-AD: Phase 2b Trial Design

    REZOLVE-AD: Phase 2b Trial Design Patients with Moderate-to-Severe Atopic Dermatitis Today’s Presentation Ongoing, Topline Q1 2026 Induction Period Maintenance Period (16 Weeks) (36 Weeks) > EASI-50 opportunity to N=104 advance to maintenance Rezpegaldesleukin 1:1 1-Year Off Treatment 24 µg/kg (q2w)

  5. Slide 5: REZOLVE-AD: Baseline Demographics

    REZOLVE-AD: Baseline Demographics  Atopic Dermatitis and Asthma: Both are common atopic diseases characterized by immune dysregulation and allergic inflammation.1  Epidemiological Evidence: Approximately 25% of patients with atopic dermatitis also have asthma, with higher risk observed in children

  6. Slide 6: Dose Dependent Percent EASI Reduction

    Dose Dependent Percent EASI Reduction Clear Separation from Placebo at All Timepoints for Study Treatment Arms All dose arms met primary endpoint with statistical significance p-value <0.001 % EASI Reduction % EASI from Baseline Reduction From(Primary Estimand) Baseline ***p-value<0.001 0 Placebo 80

  7. Slide 7: Fast Onset of Action Across All Key Secondary Endpoints

    Fast Onset of Action Across All Key Secondary Endpoints EASI-75, EASI-90, vIGA-AD 0/1, and Itch NRS (≥ 4-point Reduction) Responses Seen Early and Sustained Throughout The Primary Estimand analysis for binary endpoints use logistic regressions. Data after use of rescue therapy outside protocol speci

  8. Slide 8: Crossover from Placebo to Rezpegaldesleukin at Study Week 16

    Crossover from Placebo to Rezpegaldesleukin at Study Week 16 Deepening of Responses in Crossover Arm Support 24-Week Induction and Dose of 24 µg/kg q2w for Phase 3 Program Mean EASI % Change EASI-75 EASI-90 vIGA-AD 0/1 Itch NRS % Improvement, Mean (SEM)* 100 80 50 40 80 33% 63% Response Rate (%) Res

  9. Slide 9: EASI-75 Response for Rezpegaldesleukin 24 μg/kg q2w vs. Placebo

    EASI-75 Response for Rezpegaldesleukin 24 μg/kg q2w vs. Placebo Consistent Treatment Effect Observed Across Baseline Severity of Disease, Geographical Region and Comorbidity of Asthma Favors FavorsPlacebo Placebo Favors Rezpeg Favors REZPEG Baseline EASI < 21 (N = 73) Baseline EASI ≥ 21 (N = 104) Ba

  10. Slide 10: ACQ-5 Response in Patients with Self-Reported Asthma History

    ACQ-5 Response in Patients with Self-Reported Asthma History Improvement in ACQ-5 Scores From Baseline to Week 16 in Rezpegaldesleukin Treated Patients with Asthma Comorbidity ACQ-5 Change From ACQ-5 at Baseline and Week 16 Baseline at Week 16 (As Observed) (As Observed) 1.2 0.6 0.3 0.4 Mean (SEM) 1

  11. Slide 11: Patients with Self-Reported Asthma History and Baseline ACQ-5 ≥0.5

    Patients with Self-Reported Asthma History and Baseline ACQ-5 ≥0.5 Improvement in ACQ-5 From Baseline to Week 16 in Rezpegaldesleukin Treated Patients with Baseline ACQ-5 Score ≥ 0.5 ACQ-5 Change From Proportion of Patients with ACQ-5 ACQ-5 at Baseline and Week 16 Baseline at Week 16 Improvement of

  12. Slide 12: ACQ-5 Response in Patients with Self-Reported Uncontrolled Asthma at Baseline

    ACQ-5 Response in Patients with Self-Reported Uncontrolled Asthma at Baseline Improvement in ACQ-5 From Baseline to Week 16 in Rezpegaldesleukin Treated Patients with Baseline ACQ-5 Score ≥ 1.5 ACQ-5 Change From Proportion of Patients with ACQ-5 ACQ-5 at Baseline and Week 16 (As Observed) Baseline a

  13. Slide 13: Overall Summary of Treatment Emergent Adverse Events

    Overall Summary of Treatment Emergent Adverse Events 16-Week Induction Period Placebo q2w Rezpeg 24 µg/kg q2w Rezpeg 18 µg/kg q2w Rezpeg, 24 µg/kg q4w Rezpeg Total N = 73 N = 104 N = 106 N = 110 N = 320 Patients With at Least One TEAE 42 (57.5%) 89 (85.6%) 78 (73.6%) 90 (81.8%) 257 (80.3%) Patients

  14. Slide 14: Summary

    Summary  Rezpegaldesleukin 24 µg/kg q2w demonstrated significant improvement compared to placebo during the 16- Week induction in:  Primary: EASI LS Mean Percent Change (p<0.001)  Key Secondary: EASI-75 (p<0.001), vIGA-AD 0/1 (p<0.05), Itch NRS (p<0.01), EASI-90 (p<0.05)  Other dose levels demon

  15. Slide 15: Acknowledgements

    Acknowledgements  Thank you to:  The patients and their families  The investigators and their study teams  This study was sponsored by Nektar Therapeutics  Copies of these slides may be obtained through Quick Response (QR) code for personal use only and may not be reproduced without written per

Nektar Therapeutics — ACAAI Annual Scientific Meeting 2025 on 6ix